Abstract
In April 2019 the Institute for Clinical and Economic Review (ICER) released a report on nusinersen and onasemnogene abeparvovec-xioi (OA-xioi) compared to best supportive care (BSC) in infantile-onset spinal muscular atrophy (SMA I). ICER discussed family spillover effects for these treatments but did not implement them in the economic model. The objective of this analysis was to explore the impact of family spillover and curve fitting strategies for long-term survival prediction on the incremental cost per QALY gained from nusinersen and OA-xioi compared to BSC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have